AGP Executive Report
Last update: 8 hours agoGaza’s Health Crisis: Doctors who volunteered in Gaza say damaged hospitals and shortages of essential equipment are making treatable conditions deadly. The World Food Programme is also cutting food aid to 500,000 Palestinians because of funding shortfalls. Cancer Research: The FDA cleared Alpha Tau to double its U.S. trial of an experimental treatment for recurrent glioblastoma to 20 patients, adding measures of survival and quality of life; new data are expected Nov. 13. Drug Pipeline: The FDA accepted UroGen’s application for UGN-103, an investigational treatment for recurrent bladder cancer, with a decision expected by June 14, 2027. Hadassah Abroad: Hadassah opened a medical center in Limassol, Cyprus, offering diagnostics, specialist consultations, rehabilitation and preventive care. Israeli ministries say they were not informed and want the project’s effects on services and staffing in Israel reviewed. Mental Health: Sheba has opened a PTSD treatment center for security personnel in northern Israel, as concerns grow over the country’s post-Oct. 7 trauma burden.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
